Detalhe da pesquisa
1.
Weight gain and metabolic disturbances in people living with HIV who start antiretroviral therapy with, or switch to, bictegravir/emtricitabine/tenofovir alafenamide after 48 weeks of treatment: A real-world prospective study.
Int J STD AIDS
; 35(1): 33-38, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37729763